Share Price
Ticker: KDEV List: NASDAQ OMX
Volume:
Press Releases
-
2016-09-27
Karolinska Development portfolio company Dilafor AB raises SEK 51 million to facilitate Phase IIb clinical study with tafoxiparin
-
2016-09-20
Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research
-
2016-09-05
Stockholm September 5, 2016, Preliminary data from a retrospective study indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.
News
- 2016-09-27
Karolinska Development portfolio company Dilafor AB raises SEK 51 million to facilitate Phase IIb clinical study with tafoxiparin - 2016-09-20
Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research - 2016-09-13
Karolinska Development portfolio company Promimic AB raises SEK 23.8 million to establish commercial operations in the US - 2016-09-07
Dilaforette to present at SCD Therapeutics Conference in New York - 2016-09-05
Preliminary data from a retrospective study indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.
